nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—Mitomycin—urinary bladder cancer	0.226	0.379	CbGbCtD
Dihydroergotamine—CYP3A4—Thiotepa—urinary bladder cancer	0.102	0.172	CbGbCtD
Dihydroergotamine—ABCB1—Gemcitabine—urinary bladder cancer	0.065	0.109	CbGbCtD
Dihydroergotamine—ABCB1—Cisplatin—urinary bladder cancer	0.0472	0.0792	CbGbCtD
Dihydroergotamine—ABCB1—Etoposide—urinary bladder cancer	0.0464	0.0778	CbGbCtD
Dihydroergotamine—ABCB1—Doxorubicin—urinary bladder cancer	0.0316	0.0531	CbGbCtD
Dihydroergotamine—ABCB1—Methotrexate—urinary bladder cancer	0.0306	0.0514	CbGbCtD
Dihydroergotamine—CYP3A4—Etoposide—urinary bladder cancer	0.0278	0.0466	CbGbCtD
Dihydroergotamine—CYP3A4—Doxorubicin—urinary bladder cancer	0.019	0.0318	CbGbCtD
Dihydroergotamine—Somnolence—Gemcitabine—urinary bladder cancer	0.000642	0.00159	CcSEcCtD
Dihydroergotamine—Anorexia—Cisplatin—urinary bladder cancer	0.000642	0.00159	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—urinary bladder cancer	0.000641	0.00159	CcSEcCtD
Dihydroergotamine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000638	0.00158	CcSEcCtD
Dihydroergotamine—Discomfort—Etoposide—urinary bladder cancer	0.000636	0.00157	CcSEcCtD
Dihydroergotamine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000633	0.00157	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000633	0.00157	CcSEcCtD
Dihydroergotamine—Somnolence—Fluorouracil—urinary bladder cancer	0.000631	0.00156	CcSEcCtD
Dihydroergotamine—Hypotension—Cisplatin—urinary bladder cancer	0.000629	0.00156	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—urinary bladder cancer	0.000628	0.00155	CcSEcCtD
Dihydroergotamine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000628	0.00155	CcSEcCtD
Dihydroergotamine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000625	0.00155	CcSEcCtD
Dihydroergotamine—Fatigue—Gemcitabine—urinary bladder cancer	0.000623	0.00154	CcSEcCtD
Dihydroergotamine—Confusional state—Etoposide—urinary bladder cancer	0.000622	0.00154	CcSEcCtD
Dihydroergotamine—Muscular weakness—Epirubicin—urinary bladder cancer	0.00062	0.00154	CcSEcCtD
Dihydroergotamine—Pain—Gemcitabine—urinary bladder cancer	0.000618	0.00153	CcSEcCtD
Dihydroergotamine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000617	0.00153	CcSEcCtD
Dihydroergotamine—Asthenia—Thiotepa—urinary bladder cancer	0.000616	0.00152	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000613	0.00152	CcSEcCtD
Dihydroergotamine—Dysphagia—Epirubicin—urinary bladder cancer	0.000608	0.0015	CcSEcCtD
Dihydroergotamine—Pruritus—Thiotepa—urinary bladder cancer	0.000608	0.0015	CcSEcCtD
Dihydroergotamine—Pain—Fluorouracil—urinary bladder cancer	0.000607	0.0015	CcSEcCtD
Dihydroergotamine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000605	0.0015	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000604	0.00149	CcSEcCtD
Dihydroergotamine—Tachycardia—Etoposide—urinary bladder cancer	0.000602	0.00149	CcSEcCtD
Dihydroergotamine—Dyspnoea—Cisplatin—urinary bladder cancer	0.0006	0.00149	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000596	0.00148	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000595	0.00147	CcSEcCtD
Dihydroergotamine—Angina pectoris—Epirubicin—urinary bladder cancer	0.000592	0.00147	CcSEcCtD
Dihydroergotamine—Anorexia—Etoposide—urinary bladder cancer	0.000588	0.00145	CcSEcCtD
Dihydroergotamine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000588	0.00145	CcSEcCtD
Dihydroergotamine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000585	0.00145	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000585	0.00145	CcSEcCtD
Dihydroergotamine—Bronchitis—Epirubicin—urinary bladder cancer	0.000585	0.00145	CcSEcCtD
Dihydroergotamine—Hypotension—Etoposide—urinary bladder cancer	0.000576	0.00143	CcSEcCtD
Dihydroergotamine—Pain—Cisplatin—urinary bladder cancer	0.000576	0.00142	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000574	0.00142	CcSEcCtD
Dihydroergotamine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000571	0.00141	CcSEcCtD
Dihydroergotamine—Dizziness—Thiotepa—urinary bladder cancer	0.000568	0.00141	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000565	0.0014	CcSEcCtD
Dihydroergotamine—Urticaria—Fluorouracil—urinary bladder cancer	0.000564	0.0014	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000563	0.00139	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—urinary bladder cancer	0.000563	0.00139	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000562	0.00139	CcSEcCtD
Dihydroergotamine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000561	0.00139	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000555	0.00137	CcSEcCtD
Dihydroergotamine—Paraesthesia—Etoposide—urinary bladder cancer	0.000554	0.00137	CcSEcCtD
Dihydroergotamine—Dyspnoea—Etoposide—urinary bladder cancer	0.00055	0.00136	CcSEcCtD
Dihydroergotamine—Somnolence—Etoposide—urinary bladder cancer	0.000548	0.00136	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000548	0.00136	CcSEcCtD
Dihydroergotamine—Epistaxis—Methotrexate—urinary bladder cancer	0.000546	0.00135	CcSEcCtD
Dihydroergotamine—Vomiting—Thiotepa—urinary bladder cancer	0.000546	0.00135	CcSEcCtD
Dihydroergotamine—Rash—Thiotepa—urinary bladder cancer	0.000541	0.00134	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—urinary bladder cancer	0.000541	0.00134	CcSEcCtD
Dihydroergotamine—Dermatitis—Thiotepa—urinary bladder cancer	0.000541	0.00134	CcSEcCtD
Dihydroergotamine—Headache—Thiotepa—urinary bladder cancer	0.000538	0.00133	CcSEcCtD
Dihydroergotamine—Decreased appetite—Etoposide—urinary bladder cancer	0.000536	0.00133	CcSEcCtD
Dihydroergotamine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000532	0.00132	CcSEcCtD
Dihydroergotamine—Fatigue—Etoposide—urinary bladder cancer	0.000532	0.00132	CcSEcCtD
Dihydroergotamine—Pain—Etoposide—urinary bladder cancer	0.000527	0.00131	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000527	0.0013	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000523	0.00129	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000523	0.00129	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.00052	0.00129	CcSEcCtD
Dihydroergotamine—Asthenia—Gemcitabine—urinary bladder cancer	0.000518	0.00128	CcSEcCtD
Dihydroergotamine—Pharyngitis—Methotrexate—urinary bladder cancer	0.000516	0.00128	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—urinary bladder cancer	0.000511	0.00127	CcSEcCtD
Dihydroergotamine—Pruritus—Gemcitabine—urinary bladder cancer	0.000511	0.00126	CcSEcCtD
Dihydroergotamine—Nausea—Thiotepa—urinary bladder cancer	0.00051	0.00126	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—urinary bladder cancer	0.000509	0.00126	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000508	0.00126	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000504	0.00125	CcSEcCtD
Dihydroergotamine—Pruritus—Fluorouracil—urinary bladder cancer	0.000502	0.00124	CcSEcCtD
Dihydroergotamine—Visual impairment—Methotrexate—urinary bladder cancer	0.000501	0.00124	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000496	0.00123	CcSEcCtD
Dihydroergotamine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000494	0.00122	CcSEcCtD
Dihydroergotamine—Urticaria—Etoposide—urinary bladder cancer	0.00049	0.00121	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—urinary bladder cancer	0.000488	0.00121	CcSEcCtD
Dihydroergotamine—Abdominal pain—Etoposide—urinary bladder cancer	0.000488	0.00121	CcSEcCtD
Dihydroergotamine—Body temperature increased—Etoposide—urinary bladder cancer	0.000488	0.00121	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000488	0.00121	CcSEcCtD
Dihydroergotamine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000486	0.0012	CcSEcCtD
Dihydroergotamine—Tinnitus—Methotrexate—urinary bladder cancer	0.000485	0.0012	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000484	0.0012	CcSEcCtD
Dihydroergotamine—Asthenia—Cisplatin—urinary bladder cancer	0.000483	0.0012	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000483	0.0012	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—urinary bladder cancer	0.000473	0.00117	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000471	0.00116	CcSEcCtD
Dihydroergotamine—Dizziness—Fluorouracil—urinary bladder cancer	0.00047	0.00116	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—urinary bladder cancer	0.000469	0.00116	CcSEcCtD
Dihydroergotamine—Chills—Methotrexate—urinary bladder cancer	0.000467	0.00115	CcSEcCtD
Dihydroergotamine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000461	0.00114	CcSEcCtD
Dihydroergotamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000459	0.00114	CcSEcCtD
Dihydroergotamine—Rash—Gemcitabine—urinary bladder cancer	0.000455	0.00113	CcSEcCtD
Dihydroergotamine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000455	0.00113	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000454	0.00112	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—urinary bladder cancer	0.000454	0.00112	CcSEcCtD
Dihydroergotamine—Headache—Gemcitabine—urinary bladder cancer	0.000453	0.00112	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—urinary bladder cancer	0.000452	0.00112	CcSEcCtD
Dihydroergotamine—Vomiting—Fluorouracil—urinary bladder cancer	0.000452	0.00112	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000451	0.00112	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000448	0.00111	CcSEcCtD
Dihydroergotamine—Rash—Fluorouracil—urinary bladder cancer	0.000448	0.00111	CcSEcCtD
Dihydroergotamine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000447	0.00111	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000447	0.00111	CcSEcCtD
Dihydroergotamine—Headache—Fluorouracil—urinary bladder cancer	0.000445	0.0011	CcSEcCtD
Dihydroergotamine—Asthenia—Etoposide—urinary bladder cancer	0.000443	0.0011	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—urinary bladder cancer	0.000437	0.00108	CcSEcCtD
Dihydroergotamine—Pruritus—Etoposide—urinary bladder cancer	0.000436	0.00108	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000434	0.00107	CcSEcCtD
Dihydroergotamine—Nausea—Gemcitabine—urinary bladder cancer	0.000429	0.00106	CcSEcCtD
Dihydroergotamine—Vomiting—Cisplatin—urinary bladder cancer	0.000428	0.00106	CcSEcCtD
Dihydroergotamine—Rash—Cisplatin—urinary bladder cancer	0.000425	0.00105	CcSEcCtD
Dihydroergotamine—Dermatitis—Cisplatin—urinary bladder cancer	0.000424	0.00105	CcSEcCtD
Dihydroergotamine—Diarrhoea—Etoposide—urinary bladder cancer	0.000422	0.00104	CcSEcCtD
Dihydroergotamine—Nausea—Fluorouracil—urinary bladder cancer	0.000422	0.00104	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00042	0.00104	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00042	0.00104	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—urinary bladder cancer	0.000418	0.00103	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—urinary bladder cancer	0.000416	0.00103	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—urinary bladder cancer	0.000411	0.00102	CcSEcCtD
Dihydroergotamine—Malaise—Methotrexate—urinary bladder cancer	0.000408	0.00101	CcSEcCtD
Dihydroergotamine—Dizziness—Etoposide—urinary bladder cancer	0.000408	0.00101	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000407	0.00101	CcSEcCtD
Dihydroergotamine—Vertigo—Methotrexate—urinary bladder cancer	0.000407	0.00101	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—urinary bladder cancer	0.000404	0.001	CcSEcCtD
Dihydroergotamine—Nausea—Cisplatin—urinary bladder cancer	0.0004	0.00099	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000393	0.000973	CcSEcCtD
Dihydroergotamine—Vomiting—Etoposide—urinary bladder cancer	0.000392	0.00097	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—urinary bladder cancer	0.000389	0.000963	CcSEcCtD
Dihydroergotamine—Rash—Etoposide—urinary bladder cancer	0.000389	0.000962	CcSEcCtD
Dihydroergotamine—Dermatitis—Etoposide—urinary bladder cancer	0.000389	0.000961	CcSEcCtD
Dihydroergotamine—Headache—Etoposide—urinary bladder cancer	0.000386	0.000956	CcSEcCtD
Dihydroergotamine—Arthralgia—Methotrexate—urinary bladder cancer	0.000385	0.000954	CcSEcCtD
Dihydroergotamine—Myalgia—Methotrexate—urinary bladder cancer	0.000385	0.000954	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—urinary bladder cancer	0.000385	0.000952	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—urinary bladder cancer	0.000382	0.000945	CcSEcCtD
Dihydroergotamine—Discomfort—Methotrexate—urinary bladder cancer	0.000381	0.000942	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—urinary bladder cancer	0.000381	0.000942	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—urinary bladder cancer	0.000381	0.000942	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000377	0.000933	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—urinary bladder cancer	0.000374	0.000926	CcSEcCtD
Dihydroergotamine—Confusional state—Methotrexate—urinary bladder cancer	0.000373	0.000922	CcSEcCtD
Dihydroergotamine—Nausea—Etoposide—urinary bladder cancer	0.000366	0.000907	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—urinary bladder cancer	0.000366	0.000905	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000364	0.0009	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—urinary bladder cancer	0.000361	0.000892	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—urinary bladder cancer	0.000361	0.000892	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—urinary bladder cancer	0.00036	0.000891	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—urinary bladder cancer	0.000359	0.000889	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000357	0.000884	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—urinary bladder cancer	0.000356	0.000882	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—urinary bladder cancer	0.000354	0.000875	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—urinary bladder cancer	0.000353	0.000873	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—urinary bladder cancer	0.000352	0.000871	CcSEcCtD
Dihydroergotamine—Anorexia—Methotrexate—urinary bladder cancer	0.000352	0.000871	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—urinary bladder cancer	0.000349	0.000863	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—urinary bladder cancer	0.000346	0.000857	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—urinary bladder cancer	0.000346	0.000856	CcSEcCtD
Dihydroergotamine—Hypotension—Methotrexate—urinary bladder cancer	0.000345	0.000854	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—urinary bladder cancer	0.00034	0.000842	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—urinary bladder cancer	0.000338	0.000837	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—urinary bladder cancer	0.000337	0.000835	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000337	0.000833	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000334	0.000827	CcSEcCtD
Dihydroergotamine—Insomnia—Methotrexate—urinary bladder cancer	0.000334	0.000827	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—urinary bladder cancer	0.000334	0.000826	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000334	0.000826	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—urinary bladder cancer	0.000333	0.000823	CcSEcCtD
Dihydroergotamine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000332	0.000821	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—urinary bladder cancer	0.00033	0.000816	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—urinary bladder cancer	0.00033	0.000816	CcSEcCtD
Dihydroergotamine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000329	0.000815	CcSEcCtD
Dihydroergotamine—Somnolence—Methotrexate—urinary bladder cancer	0.000328	0.000813	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000326	0.000808	CcSEcCtD
Dihydroergotamine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000325	0.000805	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—urinary bladder cancer	0.000323	0.000799	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—urinary bladder cancer	0.000323	0.000798	CcSEcCtD
Dihydroergotamine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000321	0.000795	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—urinary bladder cancer	0.00032	0.000792	CcSEcCtD
Dihydroergotamine—Fatigue—Methotrexate—urinary bladder cancer	0.000319	0.000788	CcSEcCtD
Dihydroergotamine—Pain—Methotrexate—urinary bladder cancer	0.000316	0.000782	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000315	0.000779	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—urinary bladder cancer	0.000315	0.000779	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—urinary bladder cancer	0.000313	0.000774	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000312	0.000773	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—urinary bladder cancer	0.00031	0.000768	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000309	0.000765	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000308	0.000763	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—urinary bladder cancer	0.000307	0.000761	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—urinary bladder cancer	0.000305	0.000755	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000304	0.000753	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000304	0.000753	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000302	0.000748	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000301	0.000744	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—urinary bladder cancer	0.000299	0.00074	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—urinary bladder cancer	0.000298	0.000738	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—urinary bladder cancer	0.000296	0.000732	CcSEcCtD
Dihydroergotamine—Urticaria—Methotrexate—urinary bladder cancer	0.000294	0.000726	CcSEcCtD
Dihydroergotamine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000292	0.000723	CcSEcCtD
Dihydroergotamine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000292	0.000723	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000291	0.000721	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—urinary bladder cancer	0.000289	0.000716	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000287	0.000711	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000285	0.000706	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000285	0.000705	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—urinary bladder cancer	0.000284	0.000704	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000283	0.0007	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000282	0.000697	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000278	0.000688	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—urinary bladder cancer	0.000276	0.000683	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—urinary bladder cancer	0.000275	0.00068	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—urinary bladder cancer	0.000274	0.000677	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000273	0.000676	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000273	0.000676	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000272	0.000674	CcSEcCtD
Dihydroergotamine—Asthenia—Methotrexate—urinary bladder cancer	0.000265	0.000656	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000264	0.000652	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000262	0.000647	CcSEcCtD
Dihydroergotamine—Pruritus—Methotrexate—urinary bladder cancer	0.000261	0.000647	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000255	0.00063	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—urinary bladder cancer	0.000254	0.000629	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000253	0.000626	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000253	0.000626	CcSEcCtD
Dihydroergotamine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000253	0.000626	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—urinary bladder cancer	0.000248	0.000614	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—urinary bladder cancer	0.000245	0.000605	CcSEcCtD
Dihydroergotamine—Dizziness—Methotrexate—urinary bladder cancer	0.000244	0.000605	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000237	0.000585	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000236	0.000583	CcSEcCtD
Dihydroergotamine—Vomiting—Methotrexate—urinary bladder cancer	0.000235	0.000581	CcSEcCtD
Dihydroergotamine—Rash—Methotrexate—urinary bladder cancer	0.000233	0.000576	CcSEcCtD
Dihydroergotamine—Dermatitis—Methotrexate—urinary bladder cancer	0.000233	0.000576	CcSEcCtD
Dihydroergotamine—Headache—Methotrexate—urinary bladder cancer	0.000231	0.000573	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—urinary bladder cancer	0.00023	0.000568	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—urinary bladder cancer	0.000229	0.000566	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—urinary bladder cancer	0.000226	0.00056	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—urinary bladder cancer	0.00022	0.000544	CcSEcCtD
Dihydroergotamine—Nausea—Methotrexate—urinary bladder cancer	0.000219	0.000543	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000219	0.000542	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—urinary bladder cancer	0.000218	0.000539	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—urinary bladder cancer	0.000218	0.000539	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—urinary bladder cancer	0.000217	0.000536	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—urinary bladder cancer	0.000212	0.000523	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—urinary bladder cancer	0.000205	0.000508	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—urinary bladder cancer	0.000203	0.000503	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—urinary bladder cancer	0.000202	0.000499	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000202	0.000499	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—urinary bladder cancer	0.0002	0.000496	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—urinary bladder cancer	0.00019	0.00047	CcSEcCtD
